The work was led by David E. Olson, director of the Institute for Psychedelics and Neurotherapeutics at the University of California, Davis. Scientists in Olson’s lab and at Delix Therapeutics, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results